drugset / Trial / NCT00748579
Phase II Study of the Effect of CK-1827452 Injection on Myocardial Efficiency
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose for this study (CY 1124) is to evaluate the effects of CK-1827452, a cardiac myosin activator, on myocardial systolic performance, myocardial oxygen consumption, and myocardial efficiency in patients with heart failure and to confirm that the unique preclinical pharmacological profile of CK- 1827452 is substantially the same in patients with heart failure.
Timeline
- Start
- 2008-09
- Primary completion
- 2008-11
- Completion
- 2009-07
Outcome
Outcome not reported
Stopped (Enrollment): “Decision to discontinue due to challenges of trial design and constraints on enrolling eligible and consenting patients.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Omecamtiv Mecarbil | Small molecule | 21 mg | Intravenous |
| Subject | Omecamtiv Mecarbil | Small molecule | 36 mg | Intravenous |